

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

This circular appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of **Shanghai INT Medical Instruments Co., Ltd.*** (上海瑛泰醫療器械股份有限公司).

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Shanghai INT Medical Instruments Co., Ltd.*** (上海瑛泰醫療器械股份有限公司), you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

**(1) PROPOSED APPOINTMENT OF DR. ZHANG PENG AS AN
INDEPENDENT NON-EXECUTIVE DIRECTOR**
**(2) PROPOSED APPOINTMENT OF DR. LAI WAN LUNG AS AN
INDEPENDENT NON-EXECUTIVE DIRECTOR**
**(3) PROPOSED INCREASE IN THE INDIVIDUAL LIMIT FOR DR. LIANG
UNDER THE H SHARE AWARD AND TRUST SCHEME**
(4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
**(5) PROPOSED AMENDMENTS TO THE RULES OF
PROCEDURES FOR THE BOARD**
AND
NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

Capitalized terms used in this cover page have the same meanings as defined in this circular.

A notice convening the EGM of Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) to be held at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC on Thursday, 24 September 2026 at 2:00 p.m. is set out on pages EGM-1 to EGM-3 of this circular. A form of proxy for use at the EGM is also enclosed. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.int-medical.com).

Whether or not you are able to attend the EGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the EGM or any adjournment thereof. Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the EGM or any adjournment thereof (as the case may be) if they so wish and in such event, the form of proxy shall be deemed to be revoked.

* For identification purposes only

CONTENTS

DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I — BIOGRAPHICAL DETAILS OF INDEPENDENT NON-EXECUTIVE DIRECTORS PROPOSED FOR APPOINTMENT	14
NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026	EGM-1

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company, as amended, modified or otherwise supplemented from time to time
“Audit Committee”	the audit committee of the Board
“Board” or “Board of Directors”	the board of Directors
“Company”	Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (stock code: 1501)
“Director(s)”	the director(s) of the Company
“Dr. Liang”	Dr. Liang Dongke, the chairman of the Board and an executive Director
“EGM”	the 2026 first extraordinary general meeting of the Company or any adjournment thereof (as the case may be) to be convened at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC at 2:00 p.m. on Thursday, 24 September 2026
“H Share(s)”	overseas listed foreign invested ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Stock Exchange
“H Shareholder(s)”	holder(s) of H Share(s)
“H Share Award and Trust Scheme” or “Scheme”	the H Share award and trust scheme of the Company approved by the Board on 18 March 2022 and approved by the Shareholders on 16 May 2022 for adoption
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	2 September 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained in this circular

* For identification purposes only

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time
“Nomination Committee”	the nomination committee of the Board
“PRC”	the People’s Republic of China but excluding, for the purposes of this circular only, Hong Kong, Macau Special Administrative Region of the People’s Republic of China and Taiwan region
“PRC Company Law”	the Company Law of the People’s Republic of China, as the same may be amended, supplemented or otherwise modified from time to time
“Remuneration Committee”	the remuneration committee of the Board
“RMB”	Renminbi, the lawful currency of the PRC
“Rules of Procedures for the Board”	the rules of procedures for the Board of the Company, as amended, modified or otherwise supplemented from time to time
“Share(s)”	H Share(s)
“Shareholder(s)”	the holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Strategy and Sustainability Committee”	the strategy and sustainability committee of the Board
“Trustee”	Trident Trust Company (HK) Limited, being the trustee of the H Share Award and Trust Scheme
“treasury shares”	has the meaning ascribed to it under the Listing Rules
“%”	per cent

LETTER FROM THE BOARD



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

Executive Directors:

Dr. Liang Dongke

(Chairman and General Manager)

Mr. Lin Sen

Registered office, headquarters and

principal place of business in the PRC:

Block 2, No. 925 Jin Yuan Yi Road

Jiading District, Shanghai

the PRC

Non-executive Directors:

Dr. Song Yuan

Ms. Chen Hongqin

Mr. Zhang Hong

Ms. Chen Jie

(Employee Representative Director)

Principal place of business in Hong Kong:

31/F, Tower Two, Times Square

1 Matheson Street

Causeway Bay

Hong Kong

Independent Non-executive Directors:

Mr. Jian Xigao

Mr. Hui Hung Kwan

Mr. Xu Congli

8 September 2026

To the Shareholders

Dear Sir or Madam,

- (1) PROPOSED APPOINTMENT OF DR. ZHANG PENG AS AN
INDEPENDENT NON-EXECUTIVE DIRECTOR**
- (2) PROPOSED APPOINTMENT OF DR. LAI WAN LUNG AS AN
INDEPENDENT NON-EXECUTIVE DIRECTOR**
- (3) PROPOSED INCREASE IN THE INDIVIDUAL LIMIT FOR DR. LIANG
UNDER THE H SHARE AWARD AND TRUST SCHEME**
- (4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**
- (5) PROPOSED AMENDMENTS TO THE RULES OF
PROCEDURES FOR THE BOARD**
- AND**
- NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026**

* For identification purposes only

LETTER FROM THE BOARD

I. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in respect of the resolutions to be proposed at the EGM to be held on Thursday, 24 September 2026 to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the EGM. For the details of the proposed resolutions at the EGM, please also refer to the Notice of EGM.

At the EGM, the ordinary resolutions concerning the following matters of the Company will be proposed to consider and approve: (1) the proposed appointment of Dr. Zhang Peng as an independent non-executive Director; (2) the proposed appointment of Dr. Lai Wan Lung as an independent non-executive Director; and (3) proposed increase in the individual limit for Dr. Liang under the H Share Award and Trust Scheme.

At the EGM, the special resolutions concerning the following matters of the Company will also be proposed to consider and approve: (4) the proposed amendments to the Articles of Association; and (5) the proposed amendments to the Rules of Procedures for the Board.

II. PROPOSED APPOINTMENT OF DR. ZHANG PENG AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of the Company dated 24 August 2026 in relation to, among other things, the resignation of independent non-executive Directors and the proposed appointment of independent non-executive Directors. Given that the resignation of Mr. Jian Xigao (“**Mr. Jian**”) and Mr. Hui Hung Kwan (“**Mr. Hui**”) will result in the number of independent non-executive Directors falling below the statutory number of the Articles of Association, pursuant to the relevant provisions of the PRC Company Law and the Articles of Association, Mr. Jian and Mr. Hui will continue to perform their duties as independent non-executive Directors and members of the relevant Board committees in accordance with the applicable laws, administrative regulations, normative documents and the Articles of Association until the new independent non-executive Directors elected at the EGM take office. The resignation of Mr. Jian and Mr. Hui will take effect from the date on which the new independent non-executive Directors officially take office.

As nominated by the Shareholders and after considering the recommendations made by the Nomination Committee in accordance with the nomination policy and the board diversity policy of the Company, the Board has resolved to propose the appointment of Dr. Zhang Peng (“**Dr. Zhang**”) as a candidate for independent non-executive Director of the Fourth Session of the Board.

If appointed, Dr. Zhang will serve as an independent non-executive Director, the chairman of the Nomination Committee, and a member of the Strategy and Sustainability Committee, with his term of office from the date of approval at the EGM until the date of expiry of the Fourth Session of the Board.

LETTER FROM THE BOARD

Dr. Zhang has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the Latest Practicable Date. In accordance with the independence guidelines set forth in the Listing Rules, the Company considers Dr. Zhang to be independent, and he should be appointed as an independent non-executive Director of the Fourth Session of the Board.

The biographical details of Dr. Zhang are set out in Appendix I to this circular.

An ordinary resolution will be proposed at the EGM to consider and approve the appointment of Dr. Zhang as an independent non-executive Director of the Fourth Session of the Board.

III. PROPOSED APPOINTMENT OF DR. LAI WAN LUNG AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

As mentioned above, given that the resignation of Mr. Jian and Mr. Hui will result in the number of independent non-executive Directors falling below the statutory number of the Articles of Association, pursuant to the relevant provisions of the PRC Company Law and the Articles of Association, Mr. Jian and Mr. Hui will continue to perform their duties as independent non-executive Directors and members of the relevant Board committees in accordance with the applicable laws, administrative regulations, normative documents and the Articles of Association until the new independent non-executive Directors elected at the EGM take office. The resignation of Mr. Jian and Mr. Hui will take effect from the date on which the new independent non-executive Directors officially take office.

As nominated by the Shareholders and after considering the recommendations made by the Nomination Committee in accordance with the nomination policy and the board diversity policy of the Company, the Board has resolved to propose the appointment of Dr. Lai Wan Lung (“**Dr. Lai**”) as a candidate for independent non-executive Director of the Fourth Session of the Board.

If appointed, Dr. Lai will serve as an independent non-executive Director, the chairman of the Remuneration Committee, a member of the Audit Committee, and a member of the Strategy and Sustainability Committee, with his term of office from the date of approval at the EGM until the date of expiry of the Fourth Session of the Board.

Dr. Lai has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the Latest Practicable Date. In accordance with the

LETTER FROM THE BOARD

independence guidelines set forth in the Listing Rules, the Company considers Dr. Lai to be independent, and he should be appointed as an independent non-executive Director of the Fourth Session of the Board.

The biographical details of Dr. Lai are set out in Appendix I to this circular.

An ordinary resolution will be proposed at the EGM to consider and approve the appointment of Dr. Lai as an independent non-executive Director of the Fourth Session of the Board.

IV. PROPOSED INCREASE IN THE INDIVIDUAL LIMIT FOR DR. LIANG UNDER THE H SHARE AWARD AND TRUST SCHEME

References are made to the announcements of the Company dated 18 March 2022 and 16 May 2022, and the circular of the Company dated 12 April 2022 in relation to, among others, the proposal and approval to adopt the H Share Award and Trust Scheme. Under the H Share Award and Trust Scheme, the Company has appointed the Trustee to acquire up to 10,420,000 H Shares (the “**Scheme Limit**”) at the prevailing market prices for the H Share Award and Trust Scheme.

As at the Latest Practicable Date, the Company had a total of 211,200,000 issued H Shares (excluding treasury shares, if any), and the Trustee had purchased an aggregate of 4,356,400 H Shares, representing approximately 41.81% of the Scheme Limit. On 28 June 2026, the Company granted 33,400 H Share award shares, representing approximately 0.016% of the total issued Shares, to Dr. Liang under the H Share Award and Trust Scheme. Immediately after the completion of such grant, as at the Latest Practicable Date, the number of award shares held by the Trustee and available for future grants under the H Share Award and Trust Scheme was 4,323,000 H Shares, representing approximately 2.05% of the total issued Shares. Pursuant to the H Share Award and Trust Scheme, the aggregate number of non-vested award shares granted to any selected participant thereunder shall not exceed 1% of the total issued H Shares of the Company from time to time (the “**Individual Limit**”).

Given that (i) Dr. Liang, as the chairman, an executive Director and the general manager of the Company, plays a core leadership role in the Group’s business development and the formulation and implementation of its long-term strategy, the Board believes that granting award shares to Dr. Liang will help further align his personal interests with those of the Company and the Shareholders as a whole, thereby promoting the Company’s sustainable development; and (ii) under the relevant provisions of the PRC Company Law, shares repurchased for equity-incentive purposes must be disposed of within the prescribed period, to ensure the Company’s compliance with such regulatory requirements and its proper arrangements for the grant of award shares held by the Trustee within the prescribed period, the Board proposes to increase the Individual Limit for Dr. Liang under the H Share Award and Trust Scheme in order to reserve sufficient headroom to make appropriate award arrangements for Dr. Liang under the H Share Award and Trust Scheme in future.

LETTER FROM THE BOARD

Reference is made to the announcement of the Company dated 24 August 2026. The Board has proposed to increase the Individual Limit for Dr. Liang under the H Share Award and Trust Scheme from not exceeding 1% of the total issued H Shares (i.e., 2,112,000 H Shares as of the Latest Practicable Date) to not exceeding 50% of the Scheme Limit (i.e., 5,210,000 H Shares, representing approximately 2.47% of the total issued Shares as of the Latest Practicable Date). For the avoidance of doubt, the 33,400 H Share award shares granted to Dr. Liang under the H Share Award and Trust Scheme will be included in the increased Individual Limit.

As of the Latest Practicable Date, the Company has not made any specific arrangements for further award grants to Dr. Liang under the increased Individual Limit. Should any further grants to Dr. Liang be made under the H Share Award and Trust Scheme in future, the Company will issue further announcement(s) and/or seek Shareholders' approval (where applicable) in compliance with the Listing Rules.

Implications under the Listing Rules

The H Share Award and Trust Scheme involves only the purchasing by the Trustee of existing H Shares through transactions on the Stock Exchange, and no new Shares will be issued, nor will any options over new securities be granted, under the H Share Award and Trust Scheme. Therefore, the H Share Award and Trust Scheme will constitute a share scheme involving existing Shares under Chapter 17 of the Listing Rules, and will be subject to the provisions of the applicable provisions under Rule 17.12 of the Listing Rules. However, pursuant to the Articles of Association and the H Share Award and Trust Scheme, the resolution on the proposed increase in the Individual Limit for Dr. Liang under the H Share Award and Trust Scheme is subject to the Shareholders' approval at a general meeting of the Company.

Dr. Liang, the Company's chairman and executive Director, is a connected person of the Company under Chapter 14A of the Listing Rules. The increase in the Individual Limit for Dr. Liang does not constitute a specific transaction between the Company and Dr. Liang. Notwithstanding the above, where award shares are actually granted to Dr. Liang under the H Share Award and Trust Scheme in future, as such grants will form part of the remuneration under the service contract entered into between Dr. Liang and the Company, such grants are expected to be exempt from the reporting, announcement and independent shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

As a good corporate governance practice, Dr. Liang and his associate, Dr. Song Yuan, have abstained from voting on the resolution at the relevant Board meeting. The Board (including the independent non-executive Directors) believes that the resolution will be conducive to the Company's sustainable development and is in the interests of the Company and the Shareholders as a whole.

An ordinary resolution will be proposed at the EGM to consider and approve the increase in the Individual Limit for Dr. Liang under the H Share Award and Trust Scheme.

LETTER FROM THE BOARD

V. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Taking into account the Company's actual operating conditions, the Board proposes amendments to the Articles of Association. Details of the proposed amendments to the Articles of Association are set out below:

Before Amendment	After Amendment
Article 31 No changes resulting from share transfers may be made to the register of shareholders within 30 days prior to a shareholders' general meeting or five days prior to the record date set by the Company for the purpose of distribution of dividends.	Article 31 <u>Any change resulting from share transfers made to the register of shareholders prior to a shareholders' general meeting or the record date set by the Company for the purpose of distribution of dividends shall comply with the relevant provisions of laws, administrative regulations, rules and the securities regulatory authority of the place where the Company's shares are listed. Where the Company convenes a shareholders' general meeting, distributes dividends, conducts liquidation or other activities requiring confirmation of shareholders' identities, the Board of Directors or the convener of the shareholders' general meeting shall fix a date as the record date, and only shareholders whose names appear on the register of shareholders at the close of trading on such record date shall be entitled to the relevant rights and interests.</u>
Article 88 The Company shall have a Board of Directors consisting of 6 to 9 directors and set up one chairman. The chairman is elected by the Board of Directors with a majority vote of all directors. The chairman serves a term of 3 years and can be re-elected.	Article 88 The Company shall have a Board of Directors consisting of 6 to 9 directors and set up one chairman <u>and one employee representative director</u>. The chairman is elected by the Board of Directors with a majority vote of all directors. The chairman serves a term of 3 years and can be re-elected.

LETTER FROM THE BOARD

Before Amendment	After Amendment
Article 104 The Board of Directors shall establish a Remuneration Committee and a Nomination Committee, and the composition and rules of procedure of the specialized committees shall be separately agreed upon by the Board of Directors. If the Board of Directors fails to adopt or fully adopts the recommendations of the Remuneration Committee and Nomination Committee, the opinions of the Remuneration Committee and Nomination Committee, as well as the specific reasons for their non adoption, shall be recorded in the board resolution and disclosed.	Article 104 The Board of Directors shall establish a Remuneration Committee, a Nomination Committee <u>and a Strategy and Sustainability Committee</u>, and the composition and rules of procedure of the specialized committees shall be separately agreed upon by the Board of Directors. <u>The Strategy and Sustainability Committee is responsible for conducting research and advising on the Company's long-term development strategies, major investment decisions and sustainable development matters; conducting research and advising on the Company's major financing plans, material capital operations and production and operation projects; monitoring the execution by the management of the Company and its subsidiaries of national and local guidelines, policies, laws and regulations relating to sustainable development, environmental, social and corporate governance (ESG); guiding the Company's sustainable development and ESG work, studying the Company's ESG-related plans, targets, systems and material issues and making recommendations to the Board; studying, identifying and assessing prevailing ESG trends as well as sustainable development-related risks and opportunities associated with the Company's operations and making recommendations to the Board; reviewing the Company's ESG-related reports, reporting and making recommendations to the Board; monitoring and inspecting the implementation of ESG work and making recommendations; studying and advising on other material matters affecting the Company's development; inspecting and analysing the implementation of all aforesaid matters and proposing changes and improvements to the Board.</u>

LETTER FROM THE BOARD

Before Amendment	After Amendment
	If the Board of Directors fails to adopt or fully adopts the recommendations of the Remuneration Committee, <u>the</u> Nomination Committee <u>and the Strategy and Sustainability Committee</u>, the opinions of the Remuneration Committee, <u>the</u> Nomination Committee <u>and the Strategy and Sustainability Committee</u>, as well as the specific reasons for their non adoption, shall be recorded in the board resolution and disclosed.

The legal adviser to the Company on Hong Kong laws has confirmed that the proposed amendments comply with the requirements of the Listing Rules, and the legal adviser to the Company on the PRC laws has confirmed that the proposed amendments do not violate the PRC laws. The Company also confirms that there is nothing unusual about the proposed amendments for a joint stock company incorporated in the PRC and listed on the Stock Exchange.

A special resolution will be submitted at the EGM for the consideration and approval of the proposed amendments to the Articles of Association.

LETTER FROM THE BOARD

VI. PROPOSED AMENDMENTS TO THE RULES OF PROCEDURES FOR THE BOARD

In accordance with the requirements of the PRC Company Law, the Securities Law of the People's Republic of China, the Listing Rules as well as other relevant laws and regulations and rules, and in order to further enhance the Company's level of standardized operations and improve its corporate governance structure, taking into account the Company's actual circumstances, the Board proposes to amend the Rules of Procedures for the Board. Details of the proposed amendments to the Rules of Procedures for the Board are set out below:

Before Amendment	After Amendment
Article 4 In accordance with the Terms of Reference and Rules of Procedures of the Audit Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.*, the Terms of Reference and Rules of Procedures of the Remuneration Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.* and the Terms of Reference and Rules of Procedures of the Nomination Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.*, the Board may establish three special committees, namely the Audit Committee, the Remuneration Committee and the Nomination Committee, and may also establish other special committees as necessary.	Article 4 In accordance with the Terms of Reference and Rules of Procedures of the Audit Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.*, the Terms of Reference and Rules of Procedures of the Remuneration Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.*, the Terms of Reference and Rules of Procedures of the Nomination Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.* <u>and the Terms of Reference and Rules of Procedures of the Strategy and Sustainability Committee under the Board of Shanghai INT Medical Instruments Co., Ltd.*</u>, the Board may establish <u>four</u> special committees, namely the Audit Committee, the Remuneration Committee, the Nomination Committee <u>and the Strategy and Sustainability Committee</u>, and may also establish other special committees as necessary.

The other provisions of the Rules of Procedures for the Board remain unchanged.

A special resolution will be submitted at the EGM for the consideration and approval of the proposed amendments to the Rules of Procedures for the Board.

* For identification purposes only

LETTER FROM THE BOARD

VII. EGM

A notice convening the EGM to be held at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC on Thursday, 24 September 2026 at 2:00 p.m. is set out on pages EGM-1 to EGM-3 of this circular. A form of proxy for use at the EGM is also enclosed. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.int-medical.com).

Whether or not you are able to attend the EGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the EGM or any adjournment thereof. Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the EGM or any adjournment thereof (as the case may be) if they so wish and in such event, the form of proxy shall be deemed to be revoked.

VIII. CLOSURE OF REGISTER OF MEMBERS

Reference is made to the announcement of the Company dated 10 August 2026 in relation to the closure of register of members. For the purpose of determining the identity of the Shareholders who are entitled to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, 25 August 2026 to Thursday, 24 September 2026, both days inclusive, during which period no transfer of Shares will be effected. All transfers accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong by no later than 4:30 p.m. on Monday, 24 August 2026. The record date for determining the entitlement of the Shareholders to attend and vote at the EGM is Thursday, 24 September 2026.

IX. VOTING BY POLL

According to Rule 13.39(4) of the Listing Rules, apart from certain exceptions, any vote of Shareholders at a general meeting must be taken by poll. Treasury shares, if any, registered in the name of the Company, shall have no voting rights at the general meeting(s) of the Company. For the avoidance of doubt, treasury shares, if any, pending withdrawal from and/or transfer through CCASS shall not bear any voting rights at the Company's general meeting(s). Pursuant to Rule 17.05A of the Listing Rules, the Trustee of the H Share Award and Trust Scheme, namely Trident Trust Company (HK) Limited, holds 4,356,400 H Shares (for future grants and/or transfers upon vesting of granted awards) as at the Latest Practicable Date and will abstain from voting at the EGM. Dr. Liang has a material interest in Resolution 3 as the resolution relates to the increase in the Individual Limit for Dr. Liang under the H Share Award and Trust Scheme, Dr. Liang and his associates therefore are required to abstain from voting on the resolution to be proposed at the EGM in accordance with the Listing Rules. As

LETTER FROM THE BOARD

at the Latest Practicable Date, Dr. Liang and his associates had voting interests in 21,942,854 H Shares, representing approximately 10.39% of the total issued Shares. Save as disclosed above, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no other Shareholder has a material interest in the relevant resolution to be proposed at the EGM and is therefore required to abstain from voting on such resolution at the EGM.

On a poll, every Shareholder present in person or by proxy (or being a corporation by its duly authorized representative) shall have one vote for each Share registered in his/her/its name in the register of members. A Shareholder entitled to more than one vote needs not use all his/her/its votes or cast all the votes he/she/it has in the same manner.

X. RECOMMENDATION

The Board considers that the resolutions to be proposed at the EGM are in the interests of the Company and the Shareholders as a whole, and accordingly, recommends the Shareholders to vote in favour of each resolution to be proposed at the EGM.

XI. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

XII. MISCELLANEOUS

Unless otherwise provided herein, the English text of this circular shall prevail over the Chinese text for the purpose of interpretation.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

* For identification purposes only

APPENDIX I BIOGRAPHICAL DETAILS OF INDEPENDENT NON-EXECUTIVE DIRECTORS PROPOSED FOR APPOINTMENT

Set out below are the biographical details of the candidates proposed for appointment as independent non-executive Directors:

Dr. Zhang Peng

Dr. Zhang Peng (“**Dr. Zhang**”), aged 59. Dr. Zhang currently serves as a chief physician at the treatment and diagnostic center of interventional radiology department at Xuanwu Hospital Capital Medical University, the director and chief expert of the cerebrovascular disease center at Fujian Provincial Hospital, the director of the cerebrovascular disease diagnosis and treatment center at Heze Municipal Hospital, the vice chair of the interventional neuroradiology professional committee of the interventional radiology branch of the Chinese Society of Radiology, a member of the endovascular therapy working group of the Chinese Neurosurgical Society, a standing member of the neurointerventional professional committee of the Chinese Medical Doctor Association, a member of the neurology professional committee of the interventional branch under the Chinese Medical Doctor Association, a member of the neurointerventional branch of the Beijing Medical Association* (北京市醫學會) and a senior member of the World Federation of Neurointerventional Radiology* (世界神經介入放射聯合會). Dr. Zhang obtained a bachelor’s degree in English-taught medicine from Shandong Medical University in July 1991, and a Ph.D. in surgery from China Union Medical University* (中國協和醫科大學) in July 2001.

Dr. Zhang was nominated as a candidate for the independent non-executive Director by the Shareholders and was approved following review by the Nomination Committee. Subject to the approval of appointment of Dr. Zhang as an independent non-executive Director by the Shareholders at the EGM, the Company will enter into a service contract with Dr. Zhang. The term of office of Dr. Zhang will commence from the date of approval of his appointment at the EGM until the date of expiry of the Fourth Session of the Board, and is subject to re-election upon expiry of his term of office. Dr. Zhang’s director’s remuneration is proposed to be RMB120,000 per year (before tax), which has been determined by the Board based on the recommendations of the Remuneration Committee with reference to his duties and responsibilities as well as prevailing market conditions, and will be subject to review by the Remuneration Committee from time to time.

Dr. Zhang has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the Latest Practicable Date. Save as disclosed above, as at the Latest Practicable Date, Dr. Zhang (i) does not hold any positions within the Company or other members of the Group; (ii) does not hold any directorship in any listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, over the past three years; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and

* For identification purposes only

APPENDIX I BIOGRAPHICAL DETAILS OF INDEPENDENT NON-EXECUTIVE DIRECTORS PROPOSED FOR APPOINTMENT

(iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations. There is no other information in relation to the proposed appointment of Dr. Zhang that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders.

Dr. Lai Wan Lung

Dr. Lai Wan Lung (“**Dr. Lai**”), aged 58, currently serves as the Managing Director of master’s program in international banking and finance of Lingnan University (“**LU**”). Dr. Lai possesses governance experience in various administrative units. Specifically, he served as a member of the Council of LU, the Court of LU and the Board of Governors of the LU Institute of Further Education, respectively, and served for the campus development and management committee as well as the investment group. During the period from 2016 to 2019, he concurrently served as the founding associate director of the Graduate Faculty* (研究生部) (now known as the School of Graduate Studies), where he was responsible for developing graduate programs for the university, and also concurrently served as the director of master’s program in international higher education and management. In the field of finance, Dr. Lai is a founding member and distinguished Senior Fellow of the Hong Kong Securities and Investment Institute, where he served as a member of the units such as the Examinations Committee and the Group for Review of Misconduct Policy* (不當行為政策檢討小組). He also served as a member of the talent readiness working group of the Financial Services Development Council. Dr. Lai successively obtained his bachelor’s degree and Ph.D. in finance from Arizona State University in the United States in 1990 and 1995, respectively.

Dr. Lai was nominated as a candidate for independent non-executive Director by the Shareholders and was approved following review by the Nomination Committee. Subject to the approval of appointment of Dr. Lai as an independent non-executive Director by the Shareholders at the EGM, the Company will enter into a service contract with Dr. Lai. The term of office of Dr. Lai will commence from the date of approval of his appointment at the EGM until the date of expiry of the Fourth Session of the Board, and is subject to re-election upon expiry of his term of office. Dr. Lai’s director’s remuneration is proposed to be RMB120,000 per year (before tax), which has been determined by the Board based on the recommendations of the Remuneration Committee with reference to his duties and responsibilities as well as prevailing market conditions, and will be subject to review by the Remuneration Committee from time to time.

Dr. Lai has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the Latest Practicable Date. Save as disclosed above, as at the Latest Practicable Date, Dr. Lai (i) does not hold any positions within the Company or

* For identification purposes only

APPENDIX I BIOGRAPHICAL DETAILS OF INDEPENDENT NON-EXECUTIVE DIRECTORS PROPOSED FOR APPOINTMENT

other members of the Group; (ii) does not hold any directorship in any listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, over the past three years; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations. There is no other information in relation to the proposed appointment of Dr. Lai that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders.

NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

NOTICE IS HEREBY GIVEN THAT the extraordinary general meeting (the “EGM”) of Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the “Company”) will be held at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC on Thursday, 24 September 2026 at 2:00 p.m. for the purpose of considering and, if thought fit, passing the following resolutions:

ORDINARY RESOLUTIONS

1. To consider and approve the appointment of Dr. Zhang Peng as an independent non-executive Director of the Fourth Session of the Board
2. To consider and approve the appointment of Dr. Lai Wan Lung as an independent non-executive Director of the Fourth Session of the Board
3. To consider and approve the increase in the Individual Limit for Dr. Liang Dongke under the H Share Award and Trust Scheme

* For identification purposes only

NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

SPECIAL RESOLUTIONS

4. To consider and approve the amendments to the Articles of Association
5. To consider and approve the amendments to the Rules of Procedures for the Board

By order of the Board

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

Dr. Liang Dongke

Chairman

Shanghai, the PRC

8 September 2026

*Registered office, headquarters and principal
place of business in the PRC:*

Block 2, No. 925 Jin Yuan Yi Road

Jiading District, Shanghai, the PRC

Principal place of business in Hong Kong:

31/F, Tower Two, Times Square

1 Matheson Street, Causeway Bay

Hong Kong

Notes:

- (i) A Shareholder entitled to attend and vote at the EGM or its adjournment (as the case may be) is entitled to appoint one (or, if he/she/it holds two or more issued shares of RMB1.00 each in the Company, more than one) proxy to attend and vote, on a poll, in his/her/its stead in accordance with the Articles of Association. A proxy needs not be a Shareholder.
- (ii) A form of proxy for use at the EGM is issued and published by the Company on 8 September 2026. Whether or not you intend to attend the EGM in person, you are urged to complete and return the form of proxy in accordance with the instructions printed on the form of proxy issued and published by the Company as soon as possible. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof (as the case may be) if you so wish. In such event, your form of proxy will be deemed to have been revoked.
- (iii) A form of proxy together with any power of attorney or other authorization documents (if any) under which it is signed or a notarized copy of that power of attorney or authorization documents must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no less than 24 hours before the time appointed for holding the EGM or any adjournment thereof (as the case may be), in order to be valid.
- (iv) In order to determine the entitlement of the Shareholders to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, 25 August 2026 to Thursday, 24 September 2026, both days inclusive, during which period no transfer of Shares will be effected. All transfers accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong by no later than 4:30 p.m. on Monday, 24 August 2026. The record date for determining the entitlement of the Shareholders to attend and vote at the EGM is Thursday, 24 September 2026.

* For identification purposes only

NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

- (v) In the case of joint registered holders of any Shares, any one of such joint registered holders may vote at the EGM, either in person or by proxy, in respect of such Shares as if he/she/it were solely entitled thereto; but should more than one of such joint registered holders be present at the EGM, either in person or by proxy, the vote of that one of them so present, whose name stands first on the register of members in respect of such Shares shall be accepted to the exclusion of the votes of the other joint registered holder(s).
- (vi) The EGM is expected to take less than half a day. Shareholders who attend the EGM shall be responsible for their own travel and accommodation expenses.

As at the date of this notice, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Ms. Chen Hongqin, Mr. Zhang Hong and Ms. Chen Jie (employee representative Director) as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.